Abeona Therapeutics Inc. (ABEO) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

14/25

Growth 3 Margin 3 Expansion 2 Platform 4 Financial 2

latest quarter score

Earnings Reports

14
Abeona Therapeutics (ABEO) Q2 2026: ZEVASKYN Revenue Climbs 31% Amid Operational Launch Challenges
August 18, 2026
15
Abiona Therapeutics (ABEO) Q1 2026: ZivaSkin Drives $8.7M Launch Revenue as QTC Network Expands to Six
May 13, 2026
13
Abiona Therapeutics (ABEO) Q4 2025: ZivaSkin Patient Pool Doubles, Setting Stage for 7 QTC Ramp
March 17, 2026
12
ABEO Q3 2025: ZivaSkin Patient Pipeline Doubles, Payer Coverage Hits 80% of Commercial Lives
November 12, 2025
8
Abiona Therapeutics (ABEO) Q1 2025: $2B U.S. Revenue Potential Hinges on PZ-Cell Launch Ramp
July 06, 2025
12
Abeona Therapeutics (ABEO) FY 2024: $2B U.S. Launch Opportunity Hinges on Imminent Pz-cel FDA Approval
March 20, 2025
Abiona Therapeutics (ABEO) Q3 2024: FDA Sets April PDUFA, Supply to Lag Demand at Launch
November 14, 2024
Abiona Therapeutics (ABEO) Q1 2024: $75M Raise Extends Runway Past PZ-Cell FDA Milestones
May 15, 2024
ABEO Q4 2023: $52.6M Cash Runway Secures PZ-Cell Launch Readiness Ahead of May FDA Decision
March 18, 2024
ABEO Q3 2023: BLA Submission Sets Up $500M Peak Opportunity, Commercial Ramp in Focus
November 13, 2023
Abiona Therapeutics (ABEO) Q2 2023: $25M Raise Extends Runway Past Potential EB101 Launch
August 08, 2023
Abiona Therapeutics (ABEO) Q1 2023: EB101 Pivotal Data Drives BLA Submission Timeline and Commercial Focus
May 23, 2023
Abiona (ABEO) Q4 2022: EB101 BLA Submission Targets Late Q2 as Payer Dialogue Signals Upside
March 29, 2023

Browse all companies